| Literature DB >> 28347058 |
Puja Khanna1, Cynthia Ong2, Boon Huat Bay3, Gyeong Hun Baeg4.
Abstract
Nanoparticles are emerging as a useful tool for a wide variety of biomedical, consumer and instrumental applications that include drug delivery systems, biosensors and environmental sensors. In particular, nanoparticles have been shown to offer greater specificity with enhanced bioavailability and less detrimental side effects as compared to the existing conventional therapies in nanomedicine. Hence, bionanotechnology has been receiving immense attention in recent years. However, despite the extensive use of nanoparticles today, there is still a limited understanding of nanoparticle-mediated toxicity. Both in vivo and in vitro studies have shown that nanoparticles are closely associated with toxicity by increasing intracellular reactive oxygen species (ROS) levels and/or the levels of pro-inflammatory mediators. The homeostatic redox state of the host becomes disrupted upon ROS induction by nanoparticles. Nanoparticles are also known to up-regulate the transcription of various pro-inflammatory genes, including tumor necrosis factor-α and IL (interleukins)-1, IL-6 and IL-8, by activating nuclear factor-kappa B (NF-κB) signaling. These sequential molecular and cellular events are known to cause oxidative stress, followed by severe cellular genotoxicity and then programmed cell death. However, the exact molecular mechanisms underlying nanotoxicity are not fully understood. This lack of knowledge is a significant impediment in the use of nanoparticles in vivo. In this review, we will provide an assessment of signaling pathways that are involved in the nanoparticle- induced oxidative stress and propose possible strategies to circumvent nanotoxicity.Entities:
Keywords: DNA damage; ROS generation; apoptosis; inflammation; nanoparticles; nanotoxicity; oxidative stress
Year: 2015 PMID: 28347058 PMCID: PMC5304638 DOI: 10.3390/nano5031163
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.076
Overview of the different types of nanoparticles used in nanomedicine, and the toxicity associated.
| Class/Type of Nanoparticles | Application in Nanomedicine | Toxicity |
|---|---|---|
| Polymeric nanoparticles | ||
| Polysaccharide chitosan nanoparticles (CS-NPs) | Drug delivery [ | Not reported |
| Poly-(lactic-co-glycolic acid) (PLGA) | Cancer therapy and drug delivery [ | Not reported |
| Inorganic nanoparticles | ||
| Silica nanoparticles | Drug delivery/Diagnostic imaging [ | Platelet aggregation and physiological toxicity [ |
| Ceramic nanoparticles | Cancer drug delivery [ | Oxidative stress/cytotoxic activity in the lungs, liver, heart, and brain [ |
| Metallic nanoparticles | ||
| Superparamagnetic iron oxide nanoparticles | Magnetic resonance imaging contrast enhancement, immunoassays and cancer drug carrier systems [ | Oxidative stress and disturbance in iron homeostasis [ |
| Gold shell nanoparticles | Biomedical imaging and therapeutics [ | Hepatic and splenic toxicity [ |
| Titanium dioxide | Cancer therapeutics [ | Toxicity to the central nervous system [ |
| Silver nanoparticles | Antibacterial agents [ | ER stress response not only in the lung, liver and kidneys [ |
| Carbon nanoparticles (fullerenes and nanotubes) | Drug delivery [ | Pulmonary toxicity and interstitial inflammation [ |
Figure 1Overview of the signaling cascades mediating nanotoxicity, and possible strategies to circumvent the toxicity.